No link between the use of bisphosphonates and the risk of cancer of the esophagus or stomach has also been noted in a recent large study from the UK. This […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]

Dr. Suzanne Morin has been named a member of the Canadian Institutes of Health Research (CIHR) Institute of the Musculoskeletal Health and Arthritis Advisory Board. In this capacity Dr. Morin […]

MEET THE CMC FACULTY Dr. Cathy Craven University of Toronto  Toronto, ON Cathy Craven is the Toronto Rehabilitation Institute/ University of Toronto Chair in Spinal Cord Injury (SCI) Rehabilitation, Professor […]

St. Michael’s Hospital celebrates the 20th anniversary of the establishment of FLS St. Michael’s Hospital celebrates the 20th anniversary of the establishment of FLS St. Michael’s Hospital (SMH) in Toronto […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Bisphosphonate therapy – long term use Recently a study published by Drieling et al in JAGS 2017 described the results of a cohort study of 5120 older women with an […]

Our Senior Team Dr. Famida Jiwa President and CEO Dr. Jiwa is the President and CEO of Osteoporosis Canada, and has been with the organization since 2006. Prior to joining […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]